For more VICC news, visit their website »
Carlos L. Arteaga, M.D., the Donna S. Hall Professor of Breast Cancer and director of the Center for Cancer Targeted Therapies and the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been recognized for his cancer research efforts by the American-Italian Cancer Foundation (AICF).
Cancer affects many families, and patients and their relatives often struggle with an effective way to describe their feelings about the illness and its aftermath.
Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.
Jeffrey Rathmell, Ph.D., has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology and Immunology, the Department of Medicine and Vanderbilt-Ingram Cancer Center (VICC).
Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities.
Dan Brown, M.D., professor of Radiology and Radiological Sciences and chief of Interventional Oncology, will spearhead a national Vanderbilt-led research registry that tracks cancer patients whose tumors are treated with Yttrium-90 (Y-90), a radioactive isotope.